



Universiteit
Leiden

The Netherlands

The two faces of MuSK antibody pathogenicity and their cause and consequences in myasthenia gravis

Vergoossen, D.L.E.

Citation

Vergoossen, D. L. E. (2023, March 7). *The two faces of MuSK antibody pathogenicity and their cause and consequences in myasthenia gravis*.

Retrieved from <https://hdl.handle.net/1887/3567889>


Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3567889>

Note: To cite this publication please use the final published version (if applicable).

2





Enrichment of serum IgG4 in MuSK myasthenia gravis patients

Dana L.E. Vergoossen, Annabel M. Ruiter, Kevin R. Keene, Erik H. Niks, Martijn R. Tannemaat, Ellen Strijbos, Alexander F. Lipka, Els C. Jol-van der Zijde, Maarten J.D. van Tol, Jaap A. Bakker, Brigitte A. Wevers, Elisabet Westerberg, Lúcia S. Borges, Olivia C. Tong, David P. Richman, Isabel Illa, Anna Rostedt Punga, Amelia Evoli, Silvere M. van der Maarel, Jan J. Verschuuren* , Maartje G. Huijbers*

* shared senior authorship

Published in Journal of Neuroimmunology. 2022 Dec; 373: 577978.

Abstract

Muscle-specific kinase (MuSK) myasthenia gravis (MG) is a neuromuscular autoimmune disease belonging to a growing group of IgG4 autoimmune diseases (IgG4-AIDs), in which the majority of pathogenic autoantibodies are of the IgG4 subclass. The more prevalent form of MG with acetylcholine receptor (AChR) antibodies is caused by IgG1-3 autoantibodies. A dominant role for IgG4 in autoimmune disease is intriguing due to its anti-inflammatory characteristics. It is unclear why MuSK autoantibodies are predominantly IgG4. We hypothesized that MuSK MG patients have a general predisposition to generate IgG4 responses, therefore resulting in high levels of circulating IgG4. To investigate this, we quantified serum Ig isotypes and IgG subclasses using nephelometric and turbidimetric assays in MuSK MG and AChR MG patients not under influence of immunosuppressive treatment. Absolute serum IgG1 was increased in both MuSK and AChR MG patients compared to healthy donors. In addition, only MuSK MG patients on average had significantly increased and enriched serum IgG4. Although more MuSK MG patients had elevated serum IgG4, for most the IgG4 serum levels fell within the normal range. Correlation analyses suggest MuSK-specific antibodies do not solely explain the variation in IgG4 levels. In conclusion, although serum IgG4 levels are slightly increased, the levels do not support ubiquitous IgG4 responses in MuSK MG patients as the underlying cause of dominant IgG4 MuSK antibodies.

1. Introduction

Human immunoglobulin G (IgG) is divided into four subclasses depending on small variations in the constant domain (Fc). These variations dictate their functionalities, such as their ability to activate complement, bind to Fc receptors on immune cells or undergo Fab-arm exchange ¹. In a healthy adult population, the following reference ranges have been determined as normal by the national Dutch blood bank: IgG1 (4.9-11.4 g/L), IgG2 (1.5-6.4 g/L), IgG3 (0.11-0.85 g/L) and IgG4 (0.03-2.0 g/L) ². IgG subclass levels can be abnormal due to a deficiency of IgG subclasses (hypogammaglobulinemia) or due to abnormal ratios of subclasses (dysgammaglobulinemia). Hypogammaglobulinemia is observed in diseases affecting class switching, such as CD40 ligand or activation-induced cytidine deaminase (cofactor) deficiencies, or in immunodeficiency, centromeric region instability, facial anomalies (ICF) syndrome ^{3,4}. Dysgammaglobulinemia can be observed in for example selective IgG subclass deficiencies, monoclonal gammopathies or IgG4-related diseases ⁵⁻⁷.

Antibody-mediated autoimmune diseases are caused by antigen-specific autoantibodies, often predominantly of a specific IgG subclass. Muscle-specific kinase (MuSK) myasthenia gravis (MG) is part of a growing group of IgG4 autoimmune diseases (IgG4-AIDs), in which the majority of pathogenic autoantibodies are of the IgG4 subclass ^{8,9}. Since IgG4 has anti-inflammatory characteristics, its role in autoimmune disease was surprising at first sight. In the past decade several studies have confirmed that IgG4 is indeed responsible for the pathology observed in these IgG4-AIDs. The predominant mechanism appears to be functional blocking of its antigen rather than antigenic modulation or complement activation common to IgG1-3 autoimmune diseases ⁸. ⁹. However, why these diseases are dominated by IgG4 autoantibody responses is unknown. Altered levels of serum IgG subclasses have been found in several autoimmune diseases, such as primary Sjögren syndrome, systemic lupus erythematosus, rheumatoid arthritis, AChR MG and pemphigus ¹⁰⁻¹³. Therefore, we hypothesized that patients with IgG4-AID may have a general predisposition to generate IgG4 responses. To assess possible dysregulation in the immunoglobulin response in MuSK MG, we measured IgG subclasses, Ig isotypes and antigen-specific titers in patients not under the influence of immunosuppressive treatments.

2. Materials and methods

2.1. Subjects

MG patients were included from databases and biobanks at the Leiden University Medical Centre (LUMC, Leiden, the Netherlands), Policlinico Gemelli Università Cattolica del Sacro Cuore (Rome, Italy), Hospital Sant Pau UAB (Barcelona, Spain), Uppsala University (Uppsala, Sweden) and University of California Davis (Davis, CA, USA). The included serum samples from patients fulfilled the following criteria 1) positive for either AChR or MuSK antibodies, and 2) immunosuppression naïve or no immunosuppressive treatment for at least one year prior to the sample date. Patients who had received anti-CD20 treatment in their medical history were excluded from the study. Seventeen samples were excluded because the patients were receiving immunosuppression (IS) at time of sampling. These were used in a supplementary analysis examining IgG levels in IS vs non-IS treated patients. Samples and retrospective data were obtained from biobanks, in compliance with the institute's medical ethics committee guidelines. Demographics and clinical parameters were retrospectively collected from the medical history and gathered in an anonymized database. Sera were stored at -80 °C until analysis. Data from healthy adult donors were derived from the stem cell donor database of the Willem-Alexander Children's Hospital (LUMC, Leiden, the Netherlands).

2.2. Laboratory tests

All measurements were performed by the clinical chemistry laboratory at the LUMC under standard operating procedures based on manufacturer's instruction. IgG subclasses, total IgG, total IgA and IgM were determined using nephelometric methods on BN-prospec (Siemens; IgG subclasses, total IgG, total IgA and IgM) or the turbidimetric assay using the Cobas8000 (Roche; total IgG, IgA and IgM). Total IgE was determined using the FEIA technique on ImmunoCAP250 (Thermo Fisher Diagnostics). AChR antibody titers were determined using radioimmunoprecipitation assay (RIA, RSR) and MuSK antibody titers with either RIA (RSR), or Enzyme-linked ImmunoSorbent Assay (ELISA, IBL, IgG4-specific).

2.3. Statistical analysis

Statistical analyses were performed using SPSS statistics v25 (IBM). Demographics were analyzed with a Chi-square test (sex) or Kruskal-Wallis test (age). Absolute immunoglobulin levels were log-transformed before analysis. For group comparisons, ANCOVA with posthoc comparisons was

used and included age and sex as covariates. Elevated IgG4 proportions were tested with Fisher's Exact test.

To be able to combine MuSK antibody titers measured with the RIA and the ELISA, the values were ranked per variable for each assay separately. These sets of ranks were each converted to a scale from zero to one to normalize for the difference in the number of individuals analyzed between the two assays. The datasets for the MuSK RIA and MuSK ELISA were then combined and analyzed with a Spearman correlation.

Due to limited sample volume for some patient samples, we could not perform all predefined measurements. The group sizes available for individual measurements due to missing data are provided in the figure legends.

3. Results

3.1. Donor demographics

Sera from five medical centers were included in this study. The MuSK MG group contained relatively more female patients, while AChR MG patients were generally older at time of sampling (Table S1). These demographic characteristics match the known epidemiological patterns for MuSK MG (female predominance) and AChR MG (bimodal age of disease onset, Table S1)¹⁴. Since the groups were significantly different in sex (Chi-square test, $p=0.024$) and age (Kruskal-Wallis, $p<0.001$) (Table S1), these were included as covariates in the statistical analyses. This is important because serum IgG4 levels can depend on both^{15, 16}. Clinical information of the MG patient groups can also be found in Table S1.

3.2. Elevated and enriched serum IgG4 in MuSK MG patients

IgG subclasses were measured in MuSK MG patients and compared with AChR MG patients (IgG1-AID) and healthy donors. MuSK MG patients had increased IgG1, similar to AChR MG patients (Figure 1A). In contrast, MuSK MG patients on average had higher serum IgG4 compared to both AChR MG patients and healthy donors, while no differences between groups were detected for IgG2 and IgG3 (Figure 1B-D). In line with previous findings, males had higher IgG4 levels than females ($p<0.01$) and this holds true for all groups (Figure S1)^{15, 18}. Elevated IgG4 is defined as >1.35 g/L in IgG4-related disease¹⁷. In the MuSK MG group, 22% of patients had elevated serum IgG4 versus 3% in healthy donors and 10% in AChR MG patients, despite the female predominance in MuSK MG (Figure 1D, Fisher exact test, $p<0.01$).




Figure 1: Increased IgG4 in MuSK MG patients. Absolute values of IgG1 (A), IgG2 (B), IgG3 (C) and IgG4 (D). Dotted line at 1.35g/L represents cutoff for elevated IgG4 in IgG4-RD¹⁷. IgG1 (E), IgG2 (F), IgG3 (G) and IgG4 (H) as a percentage of the sum of the IgG subclasses. Data are presented as geometric mean and geometric 95% confidence interval (CI) in A-D and as mean and 95% CI for E-H. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. HD: $n=77$, MuSK MG: $n=27$, AChR MG: $n=50$. HD=healthy donors.

To assess whether the subclass distribution differs between groups, we calculated the percentage of each subclass versus the sum of all IgG subclasses. In AChR MG patients, the relative proportion of IgG1 was higher, while IgG2 was relatively lower (Figure 1E-F). For MuSK MG patients, the relative proportion of IgG4 was significantly higher compared to the other subclasses (Figure 1H). The IgG subclass that is increased in each MG subtype is the subclass which dominates the antigen-specific autoantibodies.

Ig isotypes were measured to investigate whether an overall dysregulation of the immunoglobulin response is present. For a subset of patients, a separate measurement of total IgG revealed increased IgG for AChR

MG and a similar trend for MuSK MG (Figure 2A). The average serum IgM level in MuSK MG patients did not significantly differ from healthy donors and AChR MG (Figure 2B). A trend towards elevated serum IgA was present in both MG groups (Figure 2C). 43% of the MuSK MG patients had elevated IgE (>99 IU/mL) versus 31% of the AChR MG patients, this was not significantly different (Fisher's exact test, $p=0.415$). In the general adult population 32% have elevated IgE¹⁹.




Figure 2: Ig Isotypes. Absolute values of IgG (A), IgM (B), IgA (C) and IgE (D). Data is presented as geometric mean and geometric 95% CI. * $p<0.05$. HD: $n=75$, MuSK MG: $n=24$ ($n=20$ for IgG, $n=21$ for IgE), AChR MG: $n=50$ ($n=44$ for IgG, $n=48$ for IgE). HD=healthy donors.

3.3. MuSK-specific titers correlate with serum IgG4

To assess whether MuSK-specific antibodies contribute to the elevated serum IgG subclass levels, the relationship between MuSK antibody titers and absolute serum IgG1 or IgG4 was investigated, as these IgG subclasses showed elevated absolute levels in MuSK MG. A spearman correlation of ranks was performed to assess this relationship, because the data is non-parametric in nature. MuSK Ab titers significantly correlated with serum IgG4 (spearman's $\rho=0.511$, $p<0.05$, $n=22$), but not with IgG1 (spearman's $\rho=0.156$, ns, $n=22$) (Figure 3). MuSK MG patients with higher serum IgG4 thus also more often have higher MuSK Ab titers.




Figure 3: MuSK antibody titers correlate with serum IgG4. Scatter plot of MuSK antibodies (Abs) versus IgG1 (A) or IgG4 (B). MuSK Abs detected by ELISA in black and by radioimmunoprecipitation assay (RIA) in grey.

4. Discussion

IgG4 MuSK antibodies cause MuSK MG and correlate with disease severity both between and within patients²⁰⁻²². In this study, we show that total serum IgG4 is increased in MuSK MG patients not under the influence of immunosuppressive treatment. MuSK MG patients with relatively high serum IgG4 also more often have relatively high MuSK titers, suggesting similar processes may underlie both. However, the observed individual variation suggests it is unlikely that the increased IgG4 levels are only due to MuSK-specific antibodies, indicating that MuSK MG patients experience an overall mild increase in IgG4 production. Absolute IgG1 levels were also elevated in both MuSK and AChR MG patients, resulting in an higher proportion of IgG1 vs all IgG subclasses in AChR MG patients only. Taken together, MuSK MG patients appear to have a (tendency to) mild increase in serum immunoglobulins, suggesting the antibody response in general may be more active. However, since circulating IgG4 levels fall within the normal range for most MuSK MG patients, it is unlikely that a predisposition to ubiquitously generate IgG4 responses causes the dominance of IgG4 antibodies targeting MuSK.

Total serum IgG4 is also selectively enriched in other IgG4-AIDs pemphigus vulgaris and pemphigus foliaceus¹². In contrast, several recent studies did not find elevated serum IgG4 in various neurological IgG4-AIDs, including MuSK MG^{18, 23, 24}. This may partly be explained by the low numbers of patient samples in these studies. Secondly, although samples were sometimes taken early in the disease course, a proportion of patients was receiving immunosuppression, which can reduce serum IgG(4) levels and thus influence how the immunoglobulin response relates to disease

activity (Figure S2, ^{25,26}). To further support the observation that increased circulating IgG4 levels are a general phenomenon in IgG4-AIDs, sera of other IgG4-AID patient groups need to be investigated prior to starting immunosuppressive therapies.

IgG4-related diseases (IgG4-RD) are hallmarked by IgG4 producing B-cell infiltrates in organs, causing swelling and dysfunction ^{17,27}. Over 50% of these patients have elevated serum IgG4 levels with some reaching an order of magnitude higher levels than normal ^{18,28}. It has been hypothesized that IgG4-RD and IgG4-AID are similar disease entities ²⁹. However, our results and previous studies in pemphigus ¹² found that serum IgG4 elevations are modest and less prevalent in IgG4-AIDs. Immune cell infiltrates have been found in pemphigus skin lesions, but it is unknown whether these are IgG4-producing B-cells ³⁰. Further, B-cell infiltrates were not observed at the neuromuscular junctions of intercostal muscles in MuSK MG patients ³¹⁻³³. Finally, IgG4-AIDs have a clear causative antigen, while this is not yet established for IgG4-RD ³⁴. Thus far, the overlap between these two disease classes is therefore limited.

The IgG4-response is associated with T helper 2 (Th2) cytokines interleukin (IL)-4, IL-13 and IL-10, regulatory T-cells and chronic antigen exposure ⁵. Class-switching to IgE and IgG4 are linked by their dependency on IL-4 or IL-13, while IL-10 appears to direct a class switch to IgG4 over IgE ⁵. The observed serum IgE levels in MuSK MG patients would be in line with a heightened Th2 response; although this was not statistically significant, likely in part because this analysis was underpowered. Surprisingly, *in vitro* activation of T-cells from MuSK MG patients suggests a higher Th1/17 versus Th2 response compared to healthy controls, although no differences could be found in plasma cytokine levels ^{35,36}. Furthermore, less IL-10-producing regulatory B-cells were found *in vivo*, and *in vitro* CD40-stimulated B-cells produced less IL-10 ^{37,38}. These results suggest that enhanced Th2 activation may not be the main driver of the IgG4 response in MuSK MG. However, the vast majority of the MuSK MG patients in these studies were on immunosuppressive medication, introducing a potential bias. An active immunization model of MuSK MG in mice did result in a predominant IgG1 (IgG4 equivalent in mouse) response accompanied by increases in IL-4 and IL-10, suggesting MuSK immunization can induce a Th2-like response ³⁹. In summary, it is yet unclear which immunological mechanisms cause the selective increase in IgG4 production or dominance in autoantibody subclass in IgG4-AIDs. In our experience it was very challenging to compile a set of samples fitting the immunosuppression naïve criteria, in spite of reaching out to 20

different MG expertise centers. The relatively low numbers studied here are a direct consequence of this and limit the study power. To further investigate the etiology of IgG4-AIDs it will be of importance to study immunosuppressive naïve serum and immune cells, as the exposure to such treatments may significantly limit our view on the immunological characteristics of these diseases.

5. Acknowledgements

We would like to thank all patients and healthy donors for donating serum and all clinicians for searching for serum from untreated MG patients. Thanks to Laurent Paardekooper for feedback on the manuscript.

6. References

1. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. *Frontiers in Immunology* 2014;5:1-17.
2. Meulenbroek AJ. Human IgG Subclasses: useful diagnostic markers for immunocompetence. 2008.
3. Durandy A, Kracker S. Immunoglobulin class-switch recombination deficiencies. *Arthritis Research & Therapy* 2012;14:218.
4. Weemaes CMR, van Tol MJD, Wang J, et al. Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects. *European Journal of Human Genetics* 2013;21:1219-1225.
5. Lighaam LC, Rispens T. The immunobiology of immunoglobulin G4. *Semin Liver Dis* 2016;36:200-215.
6. Khokar A, Gupta S. Clinical and Immunological Features of 78 Adult Patients with Primary Selective IgG Subclass Deficiencies. *Archivum Immunologiae et Therapiae Experimentalis* 2019;67:325-334.
7. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. *British Journal of Haematology* 2003;121:749-757.
8. Huijbers MG, Querol LA, Niks EH, et al. The expanding field of IgG4-mediated neurological autoimmune disorders. *European Journal of Neurology* 2015;22:1151-1161.
9. Konecny I. Update on IgG4-mediated autoimmune diseases: New insights and new family members. *Autoimmunity Reviews* 2020;19:102646.
10. Zhang H, Li P, Wu D, et al. Serum IgG subclasses in autoimmune diseases. *Medicine (Baltimore)* 2015;94:e387.
11. Liu Y, Wang W, Li J. Evaluation of serum IgG subclass concentrations in myasthenia gravis patients. *Int J Neurosci* 2011;121:570-574.
12. Funakoshi T, Lunardon L, Ellebrecht CT, Nagler AR, O'Leary CE, Payne AS. Enrichment of total serum IgG4 in patients with pemphigus. *British Journal of Dermatology* 2012;167:1245-1253.
13. Chen L-F, Mo Y-Q, Ma J-D, Luo L, Zheng D-H, Dai L. Elevated Serum IgG4 Defines Specific Clinical Phenotype of Rheumatoid Arthritis. *Mediators of Inflammation* 2014;2014:1-10.
14. Verschuuren JJ, Palace J, Gilhus NE. Clinical aspects of myasthenia explained. *Autoimmunity* 2010;43:344-352.
15. Harkness T, Fu X, Zhang Y, et al. Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race. *Ann Allergy Asthma Immunol* 2020;125:190-195 e192.
16. Aucouturier P, Danon F, Daveau M, et al. Measurement of serum IgG4 levels by a competitive immunoenzymatic assay with monoclonal antibodies. *J Immunol Methods* 1984;74:151-162.
17. Palazzo E, Palazzo C, Palazzo M. IgG4-related disease. *Joint Bone Spine* 2014;81:27-31.
18. Endmayr V, Tunc C, Ergin L, et al. Anti-Neuronal IgG4 Autoimmune Diseases and IgG4-Related Diseases May Not Be Part of the Same Spectrum: A Comparative Study. *Front Immunol* 2022;12:785247.
19. Kerkhof M, Dubois AEJ, Postma DS, Schouten JP, de Monchy JGR. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. *Allergy* 2003;58:905-911.
20. Klooster R, Plomp JJ, Huijbers MG, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. *Brain* 2012;135:1081-1101.

21. Niks EH, van Leeuwen Y, Leite MI, et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. *Journal of Neuroimmunology* 2008;195:151-156.
22. Huijbers MG, Vink AF, Niks EH, et al. Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. *J Neuroimmunol* 2016;291:82-88.
23. Basile U, Marino M, Napodano C, et al. Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients. *J Immunol Res* 2018;2018:9646209.
24. Basile U, Napodano C, Gulli F, et al. Laboratory Investigation of Hybrid IgG4 k/lambda in MuSK Positive Myasthenia Gravis. *Int J Mol Sci* 2021;22.
25. Iseda I, Hida K, Tone A, et al. Prednisolone markedly reduced serum IgG4 along with improvement of pituitary mass and anterior pituitary function in a patient with IgG4-related infundibulophypophysitis. *Endocrine Journal* 2014;61:195-203.
26. Tabata T, Kamisawa T, Takuma K, et al. Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. *Intern Med* 2011;50:69-75.
27. Bledsoe JR, Della-Torre E, Rovati L, Deshpande V. IgG4-related disease: review of the histopathologic features, differential diagnosis, and therapeutic approach. *APMIS* 2018;126:459-476.
28. Oseini AM, Chaiteerakij R, Shire AM, et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. *Hepatology* 2011;54:940-948.
29. Raibagkar P, Ferry JA, Stone JH. Is MuSK myasthenia gravis linked to IgG4-related disease? *J Neuroimmunol* 2017;305:82-83.
30. Yuan H, Zhou S, Liu Z, et al. Pivotal Role of Lesional and Perilesional T/B Lymphocytes in Pemphigus Pathogenesis. *Journal of Investigative Dermatology* 2017;137:2362-2370.
31. Niks EH, Kuks JBM, Wokke JHJ, et al. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia. *Muscle & Nerve* 2010;42:283-288.
32. Jennekens FGI, Veldman H, Vroegindeweij-Claessens LJHM, Molenaar PC, Op de Coul AAW. Congenital oculo-bulbar palsy. *Journal of Neurology, Neurosurgery, and Psychiatry* 1992;55:404-406.
33. Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? *Neurology* 2004;62:1945-1950.
34. Hubers LM, Vos H, Schuurman AR, et al. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. *Gut* 2018;67:728-735.
35. Yilmaz V, Oflazer P, Aysal F, et al. Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK. *PLOS ONE* 2015;10:e0123546.
36. Yi JS, Guidon A, Sparks S, et al. Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis. *J Autoimmun* 2014;52:130-138.
37. Yilmaz V, Oflazer P, Aysal F, et al. B cells produce less IL-10, IL-6 and TNF-alpha in myasthenia gravis. *Autoimmunity* 2015;48:201-207.
38. Sun F, Ladha SS, Yang L, et al. Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. *Muscle & Nerve* 2014;49:487-494.
39. Ulusoy C, Kim E, Tüzün E, et al. Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice. *Clinical Immunology* 2014;151:155-163.

Supplementary Material

Table S1: Donor characteristics. The percentages of MG subtype, AChE inhibitors and thymectomy are calculated from the number of patients from whom the respective data are present.

	MuSK MG n=28	AChR MG n=51	Healthy donor n=77
Sex, n (%)			
Male	9 (32)	22 (43)	46 (60)
Female	19 (68)	29 (57)	31 (40)
Age, y	39 (23.25-52)	61 (42-72)	37 (31-42)
Missing, n (%)	2 (7.1)	0 (0)	0 (0)
Age disease onset, y	39.5 (19.75-49.5)	53 (26-65)	
Missing, n (%)	2 (7.1)	0 (0)	
MG subtype, n (%)			
Ocular	0 (0)	8 (22)	
Bulbar	4 (19)	3 (8)	
Ocular Bulbar	0 (0)	1 (3)	
Generalised	17 (81)	22 (61)	
Limb-girdle	0 (0)	2 (6)	
Missing	7 (25)	15 (29)	
Immunosuppressive treatment, n (%)			
Untreated	26 (93)	45 (88)	
>1 year not treated	2 (7)	6 (12)	
AChE inhibitors, n (%)	11 (52)	37 (90)	
Missing, n (%)	7 (25)	10 (20)	
Thymectomy, n (%)	0 (0)	13 (35)	
Missing, n (%)	3 (11)	14 (38)	
Age: median (25 th -75 th percentile)			




Figure S1: Sex differences in IgG4 levels. Dotted line at 1.35g/L represents cutoff for elevated IgG4 in IgG4-RD ¹⁷. Data are presented as geometric mean. HD: n=46 (M) and n=31 (F), MuSK MG: n=9 (M) and n=18 (F), AChR MG: n=22 (M) and n=28 (F). M=male; F=female; HD=healthy donors




Figure S2: Serum IgG (A) and IgG4 (B) in patients not receiving immunosuppression (No IS, cohort of primary analysis) or independent patients that were receiving immunosuppression at time of sampling (IS, excluded from primary analysis). Characteristics of patients on IS are presented in Table S2. Data are presented as geometric mean. * $p<0.05$, ** $p<0.01$, *** $p<0.001$. MuSK MG: n=27 (No IS) and n=8 (IS), AChR MG: n=50 (No IS) and n=9 (IS).

Table S2: characteristics of patients with IS used in Figure S2

	MuSK MG + IS n=8	AChR MG + IS n=9
Sex, n (%)		
Male	4 (50)	1 (11)
Female	4 (50)	8 (89)
Age, y	50 (45-59.75)	53.5 (43.5-62.5)
Missing, n (%)	0 (0)	1 (11)
Age disease onset , y	51 (43-59.75)	38 (23-46.5)
Missing, n (%)	4 (50)	2 (22)
MG subtype, n (%)		
Ocular	0 (0)	0 (0)
Bulbar	0 (0)	0 (0)
Ocular Bulbar	0 (0)	0 (0)
Generalised	8 (100)	9 (100)
Limb-girdle	0 (0)	0 (0)
Missing	0 (0)	0 (0)
History immunosuppressive treatment, n (%)		
Prednisone	7 (87.5)	8 (89)
Azathioprine	8 (100)	8 (89)
Ciclosporine	1 (12.5)	3 (33)
IVIg	1 (12.5)	0 (0)
Plasmapheresis	1 (12.5)	1 (11)
AChE inhibitors, n (%)	4 (50)	2 (22)
Missing, n (%)	0 (0)	0 (0)
Thymectomy, n (%)	2 (25)	5 (56)
Missing, n (%)	0 (0)	0 (0)
Age: median (25 th -75 th percentile)		